Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.30USD
4:00pm EDT
Change (% chg)

$-0.05 (-1.49%)
Prev Close
$3.35
Open
$3.35
Day's High
$3.35
Day's Low
$3.20
Volume
2,258
Avg. Vol
18,270
52-wk High
$4.45
52-wk Low
$2.12

Select another date:

Thu, May 11 2017

BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56

* aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board

* aTyr Pharma announces appointment of TIMOTHY P. COUGHLIN to its board of directors Source text for Eikon: Further company coverage:

BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53

* Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018

BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines

* Atyr Pharma announces issuance of U.S. patent that extends patent protection of physiocrines derived from 20 out of 20 human TRNA synthetases Source text for Eikon: Further company coverage:

BRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris

* Atyr Pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris™ Source text for Eikon: Further company coverage:

BRIEF-Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris

* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:

BRIEF-Ecor1 Capital reports 8.3 pct passive stake in Atyr Pharma

* Ecor1 Capital LLC reports 8.3 percent passive stake in Atyr Pharma Inc as of Jan 18 - SEC filing Source text: (http://bit.ly/2kkPDsu) Further company coverage:

BRIEF-FDA grants fast track designation for aTyr's Resolaris

* Fda grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for Resolaris

Select another date:

More From Around the Web